Target LRRK2 therapy (Secarna/Scineuro)

N/A

Report date: 2024/09/13 13:57:18
NME

Base Information

Drug NameTarget LRRK2 therapy (Secarna/Scineuro)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 modulators
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSecarna Pharmaceuticals GmbH & Co KGSciNeuro Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesSciNeuro PharmaceuticalsSecarna Pharmaceuticals GmbH & Co KG
Inactive CompaniesN/A
Active IndicationsCentral Nervous System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A